Creative Biolabs has further strengthened its organ-specific targeted exosome modification platform to support advanced ...
Supported by promising data generated during the option period, Coya has entered into an exclusive license for a next-generation EET platform to enable engineering of exosomes with potential to target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results